9th Annual Biomarkers Congress

Peter D Senter

TypeWhite Paper Summary

Seattle Genetics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Our strategy is to advance our portfolio of product candidates in diseases with unmet medical need and significant market potential. We have more than 225 employees and are located in a high-technology campus in Bothell, Washington, a suburb of Seattle.

Keywords
Authors
Name:Peter D Senter

Previous Comments

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.